🔗 Share this article

An underground economy for unlicensed weight-loss drugs is propelled by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Investigational Drug Acquiring Traction Online

Retatrutide, which remains in research studies, is being advertised by social media influencers for its alleged weight-reducing properties. Viewers are encouraged to contact these profiles directly for supplier links, while also receiving promotional offers.

Thriving Trade on Social Networks

Additionally, a flourishing market exists on Telegram, where communities with thousands of members share “before and after” images, administration instructions and assertions of rapid UK delivery. Vendors market the drug there before directing customers to other platforms for purchases.

Understanding The Experimental Drug

This medication is an experimental injection developed by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could assist patients lose up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the next Ozempic.

Medical Experts Express Concerns

Nevertheless, physicians and pharmacists have warned that the sale of what remains an unapproved drug in the UK is worrisome and could lead to users administering substances of uncertain source.

Some professionals stated the demand for retatrutide could be connected to the rising price of licensed slimming products such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unlicensed drug that cannot be promoted or supplied for human use under the Human Medicines Regulations 2012.

Some influencers try to sidestep the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still violate pharmaceutical, advertising, and consumer regulations, risking fines, legal action or imprisonment.

Platform Response and Content Elimination

Based on the social media company, the service has taken down violative content and prohibited associated hashtags and search suggestions. The company said it was committed to maintaining the platform safe and investing in enhancing enforcement strategies.

Online Marketplace Operations

Investigations also discovered communities with up to 9,000 members marketing the experimental drug using Telegram's integrated discovery tool, which operates like a online catalog. Typing “retatrutide” instantly displays channels with numerous of users, populated with images of weight loss, positive reviews and detailed instructions for mixing or administering at residence.

Within moments of entering one community, a seller shared contact information, where the majority of purchases occur. The seller provided an guidebook and promised shipping within 48 hours. When questioned whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. Not one inquired about body mass, medical conditions or past usage.

Product Information and Pricing

Inside these communities, posts show black plastic packages with Royal Mail labels, claiming to include new batches. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with purified liquid, or pre-filled injectors typically sold at £160 for 20mg. When questioned how long a pen should be used, sellers give conflicting answers varying between a few weeks to “depends on your body”.

Service Oversight and Security Measures

A spokesperson for Telegram stated it regularly monitored harmful content on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“People are administering materials they cannot confirm. Even if the research behind this drug is sound, these digital versions may not include what they claim,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service connected the increase in interest to current cost increases for approved weight-loss medications such as Mounjaro. “With prices rising, individuals are using social media. But counterfeit injections are highly risky. You cannot know what’s inside or whether the environment they were produced in was sterile,” she said.

Her staff has already seen individuals injured by personal administration from unverified sources. “We understand the frustration, but buying from messaging apps or communication platforms is gambling with your well-being,” said Wyllie. “These materials could be impure or improperly measured.”

Producer Statement

A representative from the pharmaceutical company stated the substance was in third stage clinical trials and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they said, noting that any product “falsely representing itself as a company investigational substance not yet approved … may expose users to potentially significant health risks”.